Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease.

  title={Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease.},
  author={Sang-Moon Yun and Sun-Jung Cho and Chulman Jo and Moon-Ho Park and Changsu Han and Y. Koh},
  journal={Archives of gerontology and geriatrics},
INTRODUCTION Beta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) -α (sAPPα) and -β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood. METHODS The plasma protein levels of sAPPα and sAPPβ were measured… Expand
2 Citations
Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia
The differential changes in AD-related proteins were seen only in control subjects in response to iatrogenic induction of hypoglycemic insults of differing length and severity and may reflect a protective response that was absent in subjects with T2D. Expand
Hypoglycaemia in type 2 diabetes exacerbates amyloid‐related proteins associated with dementia
It is hypothesized that hypoglycaemia‐induced amyloid‐related protein changes would be exacerbated in T2D and this work demonstrated that this hypothesis was correct. Expand


Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Findings of increased concentrations of soluble amyloid-β protein precursor (sAβPP) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease and mild cognitive impairment in a large cohort of patients are confirmed and results strongly suggest that CSF sA βPP concentrations may be considered as an extension of already available NDD tools. Expand
Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
Investigation of the potential use of plasma biomarkers to diagnose AD and their relationships with brain Aβ deposition in amyloid imaging found that plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of A β deposition in the brain. Expand
CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease
Findings suggest that sAPPβ may be clinically useful, and superior to Aβ1-42, in the early and differential diagnosis of incipient AD. Expand
Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.
The data reveal that quantitive analysis of platelet sAPP-β assay by ELISA may be a novel diagnostic biomarker for MCI and AD. Expand
Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease
The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report thatExpand
Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
The results provide further evidence for a link between the two facets of AD pathology, which is likely to be mediated by the binding of Aβ oligomers to specifically targeted neurons, resulting in stimulating tau hyperphosphorylation and neurodegeneration. Expand
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
CSF biomarkers may have clinical utility in the differentiation between AD and several important differential diagnoses, including normal aging, depression, alcohol dementia, and Parkinson’s disease, and also in the identification of Creutzfeldt-Jakob disease in cases with rapidly progressive dementia. Expand
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Technical developments have given ultrasensitive measurement techniques that allow measurement of brain-specific proteins such as tau and neurofilament light (NFL) in blood samples, and a recent study showed that plasma NFL has a diagnostic performance comparable to the core AD CSF biomarkers, and predicted future cognitive decline. Expand
Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid
Down's patients have increased APP and Aβ production and increased microglial activation with age, and biomarker studies of DS may contribute to the understanding of the amyloidogenic and neurodegenerative process in AD. Expand
Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
The differential association between sAPPα and sAPPβ with Aβ and Tau species between LBD and AD groups suggests a possible relationship with the underlying pathologies in LBD or AD. Expand